FrancophonIA/ELRC3.0 huggingface dataset:
English: In cancer patients given VITRAKVI capsules, peak plasma levels (Cmax) of larotrectinib were achieved at approximately 1 hour after dosing.
Slovenian: larotrektiniba v plazmi dosežene približno 1 uro po odmerjanju.
English: Use a 1 mL syringe with 0.1 mL marks for doses less than 1 mL.
Slovenian: Za odmerke manjše od 1 ml uporabite 1 ml brizge z oznakami po 0,1 ml. Za odmerke 1 ml in več uporabite 5 ml-brizge z oznakami po 0,2 ml.
English: Myalgia Muscular weakness
Slovenian: - mišična šibkost
English: Larotrectinib Cmax was reduced by approximately 35% and there was no effect on AUC in healthy subjects administered VITRAKVI after a high-fat and high-calorie meal compared to the Cmax and AUC after overnight fasting.
Slovenian: V primerjavi z vrednostma Cmax in AUC zjutraj na tešče, pa zaužitje zdravila po obroku z visoko vsebnostjo maščob in kalorij ni imelo vpliva na vrednost
English: - VITRAKVI 25 mg is supplied as white opaque hard gelatine capsule, (18 mm long x 6 mm wide), with blue printing of BAYER-cross and “LARO 25 mg” on the body of the capsule - VITRAKVI 100 mg is supplied as white opaque hard gelatine capsule, (22 mm long x 7 mm wide), with blue printing of BAYER-cross and “LARO 100 mg” on the body of the capsule
Slovenian: VITRAKVI 25 mg trde kapsule bela, neprozorna, trda želatinasta kapsula, velikosti 2 (18 mm dolga x 6 mm široka), z modrim odtisnjenim znakom »BAYER« v obliki križa in napisom »LARO 25 mg« na telesu kapsule
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Slovenian: IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Bayer AG
English: Very common Myalgia Muscular weakness
Slovenian: Bolezni mišično skeletnega sistema in vezivnega tkiva zelo pogosti mialgija mišična šibkost pogosti mialgija mialgija mišična šibkost
English: Bayer S.p.A. Tel: +39 02 397 8 1
Slovenian: Tel: +39 02 397 8 1
English: 25 mg/m2 twice daily
Slovenian: 25 mg/m2 dvakrat na dan
English: Effect of CYP3A and P-gp inducers on larotrectinib Co-administration of VITRAKVI with strong or moderate CYP3A and P-gp inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, or St. John's Wort) may decrease larotrectinib plasma concentrations and should be avoided (see section 4.4).
Slovenian: karbamazepin, fenobarbital, fenitoin, rifabutin, rifampin ali šentjanževka) se lahko zmanjšajo koncentracije larotrektiniba v plazmi, zato se ji je treba izogibati (glejte poglavje 4.4).
English: Resume at the next dose modification if resolution occurs within 4 weeks.
Slovenian: Če neželeni učinek izzveni v 4 tednih, nadaljujte s spremenjenim odmerkom.
English: Co-administration of larotrectinib with CYP2C8, CYP2C9 or CYP2C19 substrates (e.g. repaglinide, warfarin, tolbutamide or omeprazole) may decrease their exposure.
Slovenian: Pri sočasni uporabi larotrektiniba s substrati CYP2C8, CYP2C9 ali CYP2C19 (npr.
English: Neutrophil count decreased (Neutropenia)a Leukocyte count decreased (Leukopenia)
Slovenian: (nevtropenija)a zmanjšano število levkocitov (levkopenija)
English: Alanine aminotransferase (ALT) increased Aspartate aminotransferase (AST) increased Blood alkaline phosphatase increased
Slovenian: zvišane vrednosti alkalne fosfataze v krvi zvišane vrednosti alanin aminotransferaze
English: - VITRAKVI should not be mixed with feeding formulas, if administered via nasogastric feeding tube.
Slovenian: Količino izračunanega odmerka je treba zaokrožiti na odmerek, ki je najbližje 0,2 ml. - Zdravila VITRAKVI se ne sme mešati s formulami za hranjenje, če ga dajete z nazogastrično sondo za hranjenje.
English: Common (may affect up to 1 in 10 people): - change in how things taste (dysgeusia) - increased amount of “alkaline phosphatase” in blood tests (very common in children).
Slovenian: - zvišane vrednosti »alkalne fosfataze« v izvidih krvnih preiskav (zelo pogosto pri otrocih).
English: Nausea Vomiting
Slovenian: trebušna slinavkaa
English: Each mL of oral solution contains larotrectinib sulfate, equivalent to 20 mg of larotrectinib.
Slovenian: 1 ml peroralne raztopine vsebuje larotrektinibijev sulfat, kar ustreza 20 mg larotrektiniba.
English: METHOD AND ROUTE(S) OF ADMINISTRATION Swallow whole.
Slovenian: POSTOPEK IN POT(I) UPORABE ZDRAVILA Pogoltnite celo kapsulo.
English: - The recommended dose of VITRAKVI is 100 mg (1 capsule of 100 mg or 4 capsules of 25 mg),
Slovenian: Odrasli (starejši od 18 let) - Priporočeni odmerek zdravila VITRAKVI je 100 mg (1 kapsula po 100 mg ali 4 kapsule po
English: Package leaflet: Information for the patient VITRAKVI 25 mg hard capsules VITRAKVI 100 mg hard capsules larotrectinib This medicine is subject to additional monitoring.
Slovenian: VITRAKVI 100 mg trde kapsule larotrektinib Za to zdravilo se izvaja dodatno spremljanje varnosti.
English: Alanine aminotransferase (ALT) increased Aspartate aminotransferase (AST) increased Weight increased (Abnormal weight gain) Blood alkaline phosphatase increased
Slovenian: pogosti zvišane vrednosti alkalne fosfataze v krvi zvišane vrednosti alanin aminotransferaze
English: - The maximum recommended dose is 100 mg (1 capsule of 100 mg or 4 capsules of 25 mg), two times a day.
Slovenian: - Največji priporočeni odmerek je 100 mg (1 kapsula po 100 mg ali 4 kapsule po 25 mg), dvakrat na dan. - Pediater vašega otroka bo preveril odmerek in ga po potrebi spremenil.
English: Neutrophil count decreased (Neutropenia) Leukocyte count decreased (Leukopenia)
Slovenian: zmanjšano število levkocitov (levkopenija)
English: VITRAKVI 25 mg hard capsules
Slovenian: Navodilo za uporabo VITRAKVI 25 mg trde kapsule
English: VITRAKVI 20 mg/mL oral solution
Slovenian: VITRAKVI 20 mg/ml peroralna raztopina
English: For Grade 3 or 4 adverse reactions: - VITRAKVI should be withheld until the adverse reaction resolves or improves to baseline or
Slovenian: - Uporabo zdravila VITRAKVI je treba opustiti, dokler neželeni učinek ne izzveni ali se izboljša na izhodiščno stanje ali 1. stopnjo.
English: 75 mg/m2 twice daily
Slovenian: 75 mg/m2 dvakrat na dan druga
English: 4 weeks.
Slovenian: 1,5-krat.
English: Partial response (PR)
Slovenian: Celokupni delež odziva
English: 50 mg/m2 twice daily
Slovenian: 50 mg/m2 dvakrat na dan tretja
English: Contents of the pack and other information What VITRAKVI contains
Slovenian: Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo VITRAKVI Učinkovina je larotrektinib.
English: Complete response (CR) Surgical complete responsec
Slovenian: popolni odziv (CR) popoln odziv (CR) po kirurškem poseguc delni odziv (PR) čas do prvega odziva (mediana, meseci)
English: Efficacy across tumour types
Slovenian: »košarica« pri tumorjih
English: Alanine aminotransferase (ALT) increaseda Aspartate aminotransferase (AST) increased
Slovenian: zvišane vrednosti alanin aminotransferaze
English: Kaiser-Wilhelm-Allee 51368 Leverkusen Germany
Slovenian: Kaiser-Wilhelm-Allee
English: Frequency Infants and toddlers (n=14)a
Slovenian: žleza slinavka (n = 14)
English: Dizziness Paraesthesia
Slovenian: Peroralna brizga
English: PD
Slovenian: NTRK
English: Analysis in solid tumours excluding primary CNS tumours (n=93)a
Slovenian: Analiza pri solidnih tumorjih brez primarnih tumorjev osrednjega živčevja
English: Purified water
Slovenian: Druge sestavine zdravila so: - očiščena voda
English: C.
Slovenian: AUC.
English: Nervous system disorders
Slovenian: zmanjšano število nevtrofilcev
English: Mean clearance (CL) of larotrectinib was approximately 34 L/h following intravenous administration of an IV microtracer in conjunction with a 100 mg oral dose of VITRAKVI.
Slovenian: mikrooznačevalca s 100-mg peroralnim odmerkom zdravila VITRAKVI je bil približno 34 l/h.
English: - Pull the plunger down to the graduation mark equal to the quantity in mL as prescribed.
Slovenian: - Povlecite bat navzdol do oznake, ki je enaka predpisani količini v ml. - Steklenico obrnite v pravilni položaj in odstranite peroralno brizgo z nastavka steklenice.
English: 21 years with advanced cancer or with primary CNS tumours
Slovenian: ≥ 12 let, z napredovalimi solidnimi tumorji s fuzijo genov NTRK
English: Soft tissue sarcomaa Salivary glanda Infantile fibrosarcomaa Thyroida
Slovenian: ritonavir, sakvinavir, rifabutin, efavirenz
English: Bone sarcoma (n=1) Pancreas (n=1)
Slovenian: dojke (n = 1) kostni sarkom (n = 1) trebušna slinavka (n = 1)
English: Blood and lymphatic system disorders
Slovenian: Bolezni krvi in limfatičnega sistema zelo pogosti anemija zmanjšano število nevtrofilcev
English: Natural flavour
Slovenian: - naravna aroma
English: Bayer Hungária KFT Tel:+36 14 87-41 00
Slovenian: Tel:+36 14 87-41 00
English: Paraesthesia Gait disturbance
Slovenian: Okvara ledvic
English: Very common Nausea Constipation Vomiting
Slovenian: Bolezni prebavil zelo pogosti občutek siljenja na bruhanje obstipacija bruhanje pogosti disgevzija občutek siljenja na bruhanje
English: Each capsule contains larotrectinib sulfate, equivalent to 100 mg of larotrectinib.
Slovenian: NAVEDBA ENE ALI VEČ UČINKOVIN Ena kapsula vsebuje larotrektinibijev sulfat, kar ustreza 100 mg larotrektiniba.
English: Grade 3
Slovenian: Vse stopnje
English: Sodium dihydrogen phosphate dihydrate (E 339) Citric acid (E 330)
Slovenian: - saharoza - hidroksipropilbetadeks - glicerol (E 422) - sorbitol (E 420) - natrijev citrat (E 331) - natrijev dihidrogenfosfat dihidrat (E 339) - citronska kislina (E 330) - propilenglikol (E 1520)
English: Capsule shell Gelatin
Slovenian: Ovojnica kapsule
English: How to store VITRAKVI
Slovenian: Pri odmerjanju zdravila VITRAKVI
English: Very common Dizziness Paraesthesia
Slovenian: Bolezni živčevja zelo pogosti vrtoglavica parestezija pogosti motnje hoje vrtoglavica parestezija
English: VITRAKVI 100 mg hard capsules
Slovenian: 100 mg kapsule ali
English: Primary CNSb
Slovenian: Bayer Vital GmbH
English: Paediatric patients (n=37)
Slovenian: (n = 37)
English: Infantile fibrosarcoma (n=13)
Slovenian: žleza slinavka (n = 3)
English: Atriance (nelarabine)
Slovenian: Atriance (nelarabin)
English: This schedule can also be used in patients aged 16 to 21 years.
Slovenian: To shemo je mogoče uporabljati tudi pri bolnikih, starih od 16 do 21 let.
English: Most of these side effects were also very common in children.
Slovenian: Večina neželenih učinkov je bila zelo pogosta tudi pri otrocih.
English: Further information on Atriance can be found on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/atriance
Slovenian: Dodatne informacije o zdravilu Atriance so na voljo na spletni strani agencije: https://www.ema.europa.eu/en/medicines/human/EPAR/atriance
English: The first study involved 70 children and young adults below 21 years of age.
Slovenian: Prva študija je vključevala 70 otrok in mladih odraslih, mlajših od 21 let.
English: What measures are being taken to ensure the safe and effective use of Atriance?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Atriance?
English: The European Medicines Agency decided that Atriance's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Atriance večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: The dose and frequency of infusion depend on the patient's age and body surface area (calculated using the patient's height and weight).
Slovenian: Odmerek in pogostnost infuzije sta odvisna od bolnikove starosti in telesne površine (izračunane na podlagi bolnikove telesne višine in mase).
English: This means that because the diseases are rare, it has not been possible to obtain complete information about Atriance.
Slovenian: To pomeni, da zaradi redkosti bolezni ni bilo mogoče pridobiti vseh informacij o zdravilu Atriance.
English: Atriance received a marketing authorisation valid throughout the EU on 22 August 2007.
Slovenian: Za zdravilo Atriance je bilo 22. avgusta 2007 izdano dovoljenje za promet, veljavno po vsej EU.
English: The most common side effects with Atriance in adults (which may affect more than 1 in 10 people) are infection, febrile neutropenia (low white blood cell counts with fever), neutropenia (low white blood cell counts), thrombocytopenia (low platelet counts), anaemia (low red blood cell counts), somnolence (sleepiness), peripheral neuropathy (damage to the nerves in the extremities), hypoaesthesia (a reduced sense of touch), paraesthesia (unusual sensations like pins and needles), dizziness, headache, dyspnoea (breathlessness), cough, diarrhoea, vomiting, constipation, nausea (feeling sick), myalgia (muscle pain), oedema (swelling), peripheral oedema (swelling in ankles and feet), pyrexia (fever), pain, tiredness and weakness.
Slovenian: Najpogostejši neželeni učinki zdravila Atriance pri odraslih (ki se lahko pojavijo pri več kot 1 bolniku od 10) so okužba, febrilna nevtropenija (nizko število belih krvnih celic s povišano telesno temperaturo), nevtropenija (nizko število belih krvnih celic), trombocitopenija (nizko število trombocitov), anemija (nizko število rdečih krvnih celic), somnolenca (zaspanost), periferna nevropatija (poškodba živcev v okončinah), hipestezija (zmanjšan občutek za dotik), parestezija (neobičajni občutki zbadanja), omotica, glavobol, dispneja (zasoplost), kašelj, driska, bruhanje, zaprtje, navzeja (siljenje na bruhanje), mialgija (bolečine v mišicah), edem (otekanje), periferni edem (otekanje gležnjev in stopal), pireksija (povišana telesna temperatura), bolečine, utrujenost in oslabelost.
English: This stops the production of DNA and thus slows down the growth and multiplication of cells.
Slovenian: To zaustavi nastajanje DNK, kar upočasni rast in množenje celic.
English: Of those whose cancer had not responded (28) five (18%) had a complete response to treatment.
Slovenian: Med njimi je pri tistih, ki se niso odzvali na zdravljenje (28), pet (18 %) bolnikov doseglo popoln odziv na zdravljenje.
English: Treatment should be stopped if the patient develops serious side effects affecting the brain or nervous system.
Slovenian: Zdravljenje je treba prekiniti, če se pri bolniku pojavijo resni neželeni učinki, ki prizadenejo možgane ali živčni sistem.
English: In both studies, the patients were treated with Atriance, but its effects were not compared with those of any other medicine.
Slovenian: V obeh študijah so bolniki prejemali zdravilo Atriance, vendar njegovih učinkov niso primerjali z nobenim drugim zdravilom.
English: Other information about Atriance
Slovenian: Druge informacije o zdravilu Atriance
English: Atriance has been authorised under ‘exceptional circumstances'.
Slovenian: Zdravilo Atriance je pridobilo dovoljenje za promet „v izjemnih okoliščinah“.
English: The Agency noted that, due to the small number of patients with these diseases, the information to support the authorisation of Atriance is limited, but it agreed that the medicine could allow some patients to go on to receive bone-marrow transplantation, increasing their chances of survival.
Slovenian: Ugotovila je, da so zaradi majhnega števila bolnikov s tema boleznima informacije v podporo izdaji dovoljenja za zdravilo Atriance omejene, vendar se je strinjala, da bi zdravilo utegnilo nekaterim bolnikom omogočiti presaditev kostnega mozga in tako povečati njihove možnosti za preživetje.
English: These are types of cancer where T-lymphoblasts (a type of immature white blood cell) multiply too quickly.
Slovenian: To sta vrsti raka, pri katerih se limfoblasti T (vrsta nezrelih belih krvnih celic) množijo prehitro.
English: In the second study, involving a total of 40 adults and adolescents above the age of 16.
Slovenian: Druga študija je vključevala 40 odraslih in mladostnikov, starejših od 16 let.
English: As for all medicines, data on the use of Atriance are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Atriance stalno spremljajo.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Atriance have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Atriance upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: An overview of Atriance and why it is authorised in the EU
Slovenian: Pregled zdravila Atriance in zakaj je odobreno v EU
English: Side effects reported with Atriance are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Atriance, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Nelarabine is converted within cells into an analogue of guanine, one of the fundamental chemicals that make up DNA.
Slovenian: Nelarabin se v celicah pretvori v analog gvanina, ene od osnovnih kemičnih snovi, ki tvorijo DNK.
English: Why is Atriance authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Atriance odobreno v EU?
English: What benefits of Atriance have been shown in studies?
Slovenian: Kakšne koristi zdravila Atriance so se pokazale v študijah?
English: Since Atriance has been authorised under exceptional circumstances, the company that markets Atriance will provide yearly updates from a study on the effectiveness and safety of Atriance in children and young adults.
Slovenian: Ker je zdravilo Atriance pridobilo dovoljenje za promet v izjemnih okoliščinah, bo podjetje, ki ga trži, vsako leto zagotovilo posodobljene podatke iz študije o učinkovitosti in varnosti tega zdravila pri otrocih in mladih odraslih.
English: Atriance was shown to be effective in two main studies involving patients with T-ALL and T-LBL whose cancer had stopped responding to one or more previous cancer treatments.
Slovenian: Učinkovitost zdravila Atriance so dokazali v dveh glavnih študijah, ki so vključevale bolnike s T-ALL in T-LBL, ki so se prenehali odzivati na eno ali več predhodnih zdravljenj raka.
English: Patients aged under 16 years receive a dose of 650 mg per square metre given over one hour on five consecutive days, repeated every 21 days.
Slovenian: Bolniki, mlajši od 16 let, prejmejo odmerek 650 mg na kvadratni meter telesne površine v enournem obdobju pet zaporednih dni, pri čemer se zdravljenje ponovi vsakih 21 dni.
English: For more information about using Atriance, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Atriance glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Atriance is used when the cancer has not responded to, or has stopped responding to, at least two types of chemotherapy.
Slovenian: Zdravilo Atriance se uporablja pri bolnikih z rakom, ki se niso odzvali ali pa so se prenehali odzivati na najmanj dve vrsti kemoterapije.
English: Severe side effects affecting the brain and nervous system have also been reported in patients taking Atriance, including somnolence, convulsions, and peripheral neuropathy causing numbness, unusual sensations, weakness and even paralysis.
Slovenian: Pri bolnikih, ki so jemali zdravilo, so poročali o resnih neželenih učinkih, ki prizadenejo možgane ali živčni sistem, vključno z zaspanostjo, konvulzijami in periferno nevropatijo, ki povzroča odrevenelost, neobičajne občutke, oslabelost in celo paralizo.
English: What is Atriance and what is it used for?
Slovenian: Kaj je zdravilo Atriance in za kaj se uporablja?
English: Patients receiving Atriance should be monitored regularly for changes in blood cell counts and should receive adequate hydration if they are at risk of tumour lysis syndrome (a complication due to the breakdown of cancer cells).
Slovenian: Pri bolnikih, ki prejemajo zdravilo Atriance, je treba redno nadzirati spremembe krvne slike, poleg tega morajo zaužiti dovolj tekočine, če pri njih obstaja tveganje za pojav sindroma tumorske lize (zapleta zaradi razgradnje rakavih celic).
English: What are the risks associated with Atriance?
Slovenian: Kakšna tveganja so povezana z zdravilom Atriance?
English: In adults and adolescents aged 16 years and over, the recommended starting dose is 1,500 mg per square metre of body surface area, given over two hours on days one, three and five, repeated every 21 days.
Slovenian: Pri odraslih in mladostnikih, starih 16 let ali več, znaša priporočeni začetni odmerek 1 500 mg na kvadratni meter telesne površine, ki ga bolnik prejema v dvournem obdobju na prvi, tretji in peti dan, pri čemer se zdravljenje ponovi vsakih 21 dni.
English: In both studies, compared to patients who had a complete response more patients had a partial response to Atriance treatment, with blood counts returning towards normal levels.
Slovenian: V obeh študijah se je v primerjavi z bolniki s popolnim odzivom več bolnikov delno odzvalo na zdravljenje z zdravilom, pri čemer se je število krvnih celic približalo normalni ravni.
English: Atriance can only be obtained with a prescription and is given by drip into a vein under the supervision of a doctor who has experience in the use of thes type of medicine.
Slovenian: Predpisovanje in izdaja zdravila Atriance je le na recept, daje pa se s kapalno infuzijo v veno pod nadzorom zdravnika, ki ima izkušnje z uporabo tovrstnih zdravil.
English: Because the guanine analogue accumulates in Tcells and lasts longer in these cells, Atriance slows down the growth and multiplication of the cells involved in T-ALL and T-LBL.
Slovenian: Ker se analog gvanina kopiči v celicah T in je v njih obstojnejši, zdravilo Atriance upočasni rast in množenje celic pri T-ALL in T-LBL.
English: Of those whose cancer had not responded to two or more previous treatments (39) five (13%) had a complete response to treatment after a month, with no evidence of disease and normal blood counts.
Slovenian: Med njimi je pri tistih, ki se niso odzvali na najmanj dve predhodni zdravljenji raka (39), po enem mesecu doseglo popoln odziv na zdravljenje pet bolnikov (13 %), pri čemer niso imeli več znakov bolezni, njihova krvna slika pa je bila normalna.
English: Atriance is a cancer medicine used to treat patients with T-cell acute lymphoblastic leukaemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL).
Slovenian: Atriance je zdravilo za zdravljenje raka in se uporablja za zdravljenje bolnikov z akutno limfoblastno levkemijo celic T (T-ALL) ali limfoblastnim limfomom celic T (T-LBL).
English: Agency will review any new information that may become available and this overview will be updated as necessary.
Slovenian: Agencija bo vsako leto ponovno pregledala vse nove podatke, ki bodo na voljo.
English: What information is still awaited for Atriance?
Slovenian: Katere informacije o zdravilu Atriance še pričakujemo?
English: The active substance in Atriance, nelarabine, is a cytotoxic, a medicine that kills cells that are dividing, such as cancer cells.
Slovenian: Učinkovina v zdravilu Atriance, nelarabin, je citotoksik, tj. zdravilo, ki uničuje celice, ki se delijo, na primer rakave celice.
English: How does Atriance work?
Slovenian: Kako zdravilo Atriance deluje?
English: Patients should be monitored closely for these side effects and treatment stopped if necessary.
Slovenian: Morebitni pojav neželenih učinkov je treba pri bolnikih skrbno nadzirati in zdravljenje po potrebi prekiniti.
English: For the full list of side effects and restrictions of Atriance, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev, o katerih so poročali pri uporabi zdravila Atriance, glejte navodilo za uporabo.
English: Atriance contains the active substance nelarabine.
Slovenian: Zdravilo Atriance vsebuje učinkovino nelarabin.
English: In the body, this analogue takes the place of guanine and interferes with the enzymes involved in making new DNA, DNA polymerases.
Slovenian: Ta analog v telesu zavzame mesto gvanina in ovira DNK polimeraze, tj. encime, ki sodelujejo pri tvorjenju nove DNK.
English: Treatment may be delayed if other side effects occur.
Slovenian: Če se pojavijo drugi neželeni učinki, se lahko odmerki dajejo z daljšimi presledki.